BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes 2013;11:161. [PMID: 24088389 DOI: 10.1186/1477-7525-11-161] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schüler R, Wiklund I, Peacock A; IRB information for the 5 clinical sites. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH. Respir Res 2016;17:72. [PMID: 27301413 DOI: 10.1186/s12931-016-0388-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
2 Banerjee D, Kamuren J, Baird GL, Palmisciano A, Krishnan I, Whittenhall M, Klinger JR, Ventetuolo CE. The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension. Pulm Circ 2017;7:384-90. [PMID: 28597751 DOI: 10.1177/2045893217695568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
3 Hidayati F, Gharini PPR, Hartopo AB, Anggrahini DW, Dinarti LK. The effect of oral sildenafil therapy on health-related quality of life in adults with pulmonary arterial hypertension related to uncorrected secundum atrial septal defect: a quasi experimental study. Health Qual Life Outcomes 2020;18:278. [PMID: 32795300 DOI: 10.1186/s12955-020-01498-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Gater A, Rofail D, Marshall C, Tolley C, Abetz-Webb L, Zarit SH, Berardo CG. Assessing the Impact of Caring for a Person with Schizophrenia: Development of the Schizophrenia Caregiver Questionnaire. Patient 2015;8:507-20. [PMID: 25680337 DOI: 10.1007/s40271-015-0114-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
5 Sood N, Aranda A, Platt D, LaRose A, Kleinjung F, O'Brien G. Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION study. Pulm Circ 2019;9:2045894018823715. [PMID: 30574833 DOI: 10.1177/2045894018823715] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
6 McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, Mehta S, Murakami N, Wong BA. The importance of patient perspectives in pulmonary hypertension. Eur Respir J 2019;53:1801919. [PMID: 30545977 DOI: 10.1183/13993003.01919-2018] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 16.3] [Reference Citation Analysis]
7 Frantz RP, Chin KM, Zhao C, Flynn M, Badesch D. Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting. Pulm Circ 2020;10:2045894020923957. [PMID: 32489644 DOI: 10.1177/2045894020923957] [Reference Citation Analysis]
8 Borgese M, Badesch D, Bull T, Chakinala M, DeMarco T, Feldman J, Ford HJ, Grinnan D, Klinger JR, Bolivar L, Shlobin OA, Frantz RP, Sager JS, Mathai SC, Kawut S, Leary PJ, Gray MP, Popat RA, Zamanian RT; PHAR Study Group. EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR. Eur Respir J 2021;57:2000414. [PMID: 33243844 DOI: 10.1183/13993003.00414-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ulrich S, Grunig E. The patient tells it! The importance of patient's quality of life perception in pulmonary arterial hypertension risk assessment. Eur Respir J 2021;57:2004376. [DOI: 10.1183/13993003.04376-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 LeVarge BL, Channick RN. The changing paradigm in pulmonary hypertension trials: longer duration, new endpoints. Curr Opin Pulm Med 2015;21:438-45. [PMID: 26176969 DOI: 10.1097/MCP.0000000000000197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and impact on quality of life. Eur Respir Rev 2015;24:621-9. [PMID: 26621976 DOI: 10.1183/16000617.0063-2015] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 12.3] [Reference Citation Analysis]
12 Rawlings GH, Beail N, Armstrong I, Condliffe R, Kiely DG, Sabroe I, Thompson AR. Adults' experiences of living with pulmonary hypertension: a thematic synthesis of qualitative studies. BMJ Open 2020;10:e041428. [PMID: 33293321 DOI: 10.1136/bmjopen-2020-041428] [Reference Citation Analysis]
13 Mathai SC, Minai O, Sullivan SD, Lerner D, Levine D. Rationale and study design of MOTION: A phase 4, prospective, single-arm, open-label study to measure outcomes in patients with pulmonary arterial hypertension not on active treatment. Respir Med 2017;122 Suppl 1:S23-7. [PMID: 27890471 DOI: 10.1016/j.rmed.2016.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Odevoglu P, Demir R, Okumus G, Kucukoglu MS, Kuran Aslan G. Validity and reliability of the Turkish version of the E m PH asis‐10 questionnaire in patients with pulmonary hypertension. J Eval Clin Pract 2019;25:896-902. [DOI: 10.1111/jep.13115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
15 Chin KM, Gomberg-Maitland M, Channick RN, Cuttica MJ, Fischer A, Frantz RP, Hunsche E, Kleinman L, McConnell JW, McLaughlin VV, Miller CE, Zamanian RT, Zastrow MS, Badesch DB. Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. Chest 2018;154:848-61. [PMID: 29705220 DOI: 10.1016/j.chest.2018.04.027] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
16 Reis A, Santos M, Furtado I, Cruz C, Sa-Couto P, Queirós A, Almeida L, Rocha N. Disability and its clinical correlates in pulmonary hypertension measured through the World Health Organization Disability Assessment Schedule 2.0: a prospective, observational study. J Bras Pneumol 2019;45:e20170355. [PMID: 31166372 DOI: 10.1590/1806-3713/e20170355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Klinger JR, Chakinala MM, Langleben D, Rosenkranz S, Sitbon O. Riociguat: Clinical research and evolving role in therapy. Br J Clin Pharmacol 2021;87:2645-62. [PMID: 33242341 DOI: 10.1111/bcp.14676] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Fernandes CJ, Martins BC, Jardim CV, Ciconelli RM, Morinaga LK, Breda AP, Hoette S, Souza R. Quality of life as a prognostic marker in pulmonary arterial hypertension. Health Qual Life Outcomes 2014;12:130. [PMID: 25176512 DOI: 10.1186/s12955-014-0130-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
19 Mathai SC, Ghofrani HA, Mayer E, Pepke-Zaba J, Nikkho S, Simonneau G. Quality of life in patients with chronic thromboembolic pulmonary hypertension. Eur Respir J 2016;48:526-37. [PMID: 27076580 DOI: 10.1183/13993003.01626-2015] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
20 Banerjee D, Vargas SE, Guthrie KM, Wickham BM, Allahua M, Whittenhall ME, Palmisciano AJ, Ventetuolo CE. Sexual health and health-related quality of life among women with pulmonary arterial hypertension. Pulm Circ 2018;8:2045894018788277. [PMID: 30124126 DOI: 10.1177/2045894018788277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Yen W, Sommerich CM, Lavender SA, Flinn SR, Sanders EB. Evaluation of jar lid design characteristics by older women with hand use limitations. Applied Ergonomics 2016;52:177-84. [DOI: 10.1016/j.apergo.2015.07.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
22 Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S. Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life. Chest 2014;146:686-708. [DOI: 10.1378/chest.13-2634] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
23 Ghofrani HA, Humbert M, Langleben D, Schermuly R, Stasch JP, Wilkins MR, Klinger JR. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest 2017;151:468-80. [PMID: 27263466 DOI: 10.1016/j.chest.2016.05.024] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 8.2] [Reference Citation Analysis]
24 Bunclark K, Doughty N, Michael A, Abraham N, Ali S, Cannon JE, Sheares K, Speed N, Taboada D, Toshner M, Pepke-Zaba J. A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension. Pulm Circ 2021;11:2045894021995055. [PMID: 34104417 DOI: 10.1177/2045894021995055] [Reference Citation Analysis]
25 Newnham M, Bunclark K, Abraham N, Ali S, Amaral-almeida L, Cannon JE, Doughty N, Ng C, Ponnaberanam A, Sheares K, Speed N, Taboada D, Toshner M, Tsui S, Jenkins DP, Pepke-zaba J. CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. Eur Respir J 2020;56:1902096. [DOI: 10.1183/13993003.02096-2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]